Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury

Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular physiology 2021-04, Vol.236 (4), p.2893-2905
Hauptverfasser: Kovacs‐Kasa, Anita, Kovacs, Laszlo, Cherian‐Shaw, Mary, Patel, Vijay, Meadows, Mary L., Fulton, David J., Su, Yunchao, Verin, Alexander D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2905
container_issue 4
container_start_page 2893
container_title Journal of cellular physiology
container_volume 236
creator Kovacs‐Kasa, Anita
Kovacs, Laszlo
Cherian‐Shaw, Mary
Patel, Vijay
Meadows, Mary L.
Fulton, David J.
Su, Yunchao
Verin, Alexander D.
description Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization. Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.
doi_str_mv 10.1002/jcp.30053
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jcp_30053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2488831038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</originalsourceid><addsrcrecordid>eNp1kUFvFCEYhonR2LV68A8YEk8epoVh2IGLSTNqu02TetAzAeajy2YWVphp3Zs_wd_oL5F22kYPPUHyPjx8X16E3lJyRAmpjzd2d8QI4ewZWlAi26pZ8vo5WpSMVpI39AC9ynlDCJGSsZfogNWSSyH5Ag2rsPbGjz4GHB3uBp0zXq00Pvt00mXst7sUryFjCH0c1zB4PWCjU_KQsJuCvXvow5zHnz78-fXbh36y0GNtpxHwMIWrQmymtH-NXjg9ZHhzfx6i718-f-vOqovL01V3clHZpmGsMq0QQMBx00JruBGtoJqwcrUtq2srCRHcUen61gE0xom-5czWBpZuqcuKh-jj7N1NZgu9hTAmPahd8lud9ipqr_5Pgl-rq3itpGyWlNEieH8vSPHHBHlUmzilUGZWdSOEYJQwUagPM2VTzDmBe_yBEnVbjCrFqLtiCvvu35EeyYcmCnA8Azd-gP3TJnXefZ2VfwHRhJre</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2488831038</pqid></control><display><type>article</type><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</creator><creatorcontrib>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</creatorcontrib><description>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization. Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.30053</identifier><identifier>PMID: 32959895</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetylation ; acute lung injury ; Acute Lung Injury - chemically induced ; Acute Lung Injury - enzymology ; Acute Lung Injury - physiopathology ; Adaptor Proteins, Signal Transducing - metabolism ; Animal models ; Animals ; barrier protection ; Cell Membrane Permeability - drug effects ; Class IIA HDACs inhibition ; Contractility ; Cytoskeleton ; Depletion ; Disease Models, Animal ; Endothelial cells ; Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Endotoxins ; Heart Rate - drug effects ; Histone deacetylase ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylases - metabolism ; Inflammatory diseases ; Inhibitors ; Lipopolysaccharides ; LPS ; Lung - drug effects ; Lung - pathology ; Lung - physiopathology ; Lungs ; Mice ; Mice, Inbred C57BL ; Microvasculature ; Microvessels - pathology ; Models, Biological ; Myosin ; Oxygen - metabolism ; Permeability ; Phosphorylation ; Pneumonia - complications ; Pneumonia - pathology ; pulmonary endothelium ; Respiratory function ; rho GTP-Binding Proteins - metabolism ; Signal Transduction - drug effects ; TMP269 ; Tubulin</subject><ispartof>Journal of cellular physiology, 2021-04, Vol.236 (4), p.2893-2905</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</citedby><cites>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</cites><orcidid>0000-0003-0627-7185 ; 0000-0001-7244-5517</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.30053$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.30053$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32959895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovacs‐Kasa, Anita</creatorcontrib><creatorcontrib>Kovacs, Laszlo</creatorcontrib><creatorcontrib>Cherian‐Shaw, Mary</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Meadows, Mary L.</creatorcontrib><creatorcontrib>Fulton, David J.</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization. Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</description><subject>Acetylation</subject><subject>acute lung injury</subject><subject>Acute Lung Injury - chemically induced</subject><subject>Acute Lung Injury - enzymology</subject><subject>Acute Lung Injury - physiopathology</subject><subject>Adaptor Proteins, Signal Transducing - metabolism</subject><subject>Animal models</subject><subject>Animals</subject><subject>barrier protection</subject><subject>Cell Membrane Permeability - drug effects</subject><subject>Class IIA HDACs inhibition</subject><subject>Contractility</subject><subject>Cytoskeleton</subject><subject>Depletion</subject><subject>Disease Models, Animal</subject><subject>Endothelial cells</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Endotoxins</subject><subject>Heart Rate - drug effects</subject><subject>Histone deacetylase</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Histone Deacetylases - metabolism</subject><subject>Inflammatory diseases</subject><subject>Inhibitors</subject><subject>Lipopolysaccharides</subject><subject>LPS</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Lung - physiopathology</subject><subject>Lungs</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microvasculature</subject><subject>Microvessels - pathology</subject><subject>Models, Biological</subject><subject>Myosin</subject><subject>Oxygen - metabolism</subject><subject>Permeability</subject><subject>Phosphorylation</subject><subject>Pneumonia - complications</subject><subject>Pneumonia - pathology</subject><subject>pulmonary endothelium</subject><subject>Respiratory function</subject><subject>rho GTP-Binding Proteins - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>TMP269</subject><subject>Tubulin</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFvFCEYhonR2LV68A8YEk8epoVh2IGLSTNqu02TetAzAeajy2YWVphp3Zs_wd_oL5F22kYPPUHyPjx8X16E3lJyRAmpjzd2d8QI4ewZWlAi26pZ8vo5WpSMVpI39AC9ynlDCJGSsZfogNWSSyH5Ag2rsPbGjz4GHB3uBp0zXq00Pvt00mXst7sUryFjCH0c1zB4PWCjU_KQsJuCvXvow5zHnz78-fXbh36y0GNtpxHwMIWrQmymtH-NXjg9ZHhzfx6i718-f-vOqovL01V3clHZpmGsMq0QQMBx00JruBGtoJqwcrUtq2srCRHcUen61gE0xom-5czWBpZuqcuKh-jj7N1NZgu9hTAmPahd8lud9ipqr_5Pgl-rq3itpGyWlNEieH8vSPHHBHlUmzilUGZWdSOEYJQwUagPM2VTzDmBe_yBEnVbjCrFqLtiCvvu35EeyYcmCnA8Azd-gP3TJnXefZ2VfwHRhJre</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Kovacs‐Kasa, Anita</creator><creator>Kovacs, Laszlo</creator><creator>Cherian‐Shaw, Mary</creator><creator>Patel, Vijay</creator><creator>Meadows, Mary L.</creator><creator>Fulton, David J.</creator><creator>Su, Yunchao</creator><creator>Verin, Alexander D.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0627-7185</orcidid><orcidid>https://orcid.org/0000-0001-7244-5517</orcidid></search><sort><creationdate>202104</creationdate><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><author>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acetylation</topic><topic>acute lung injury</topic><topic>Acute Lung Injury - chemically induced</topic><topic>Acute Lung Injury - enzymology</topic><topic>Acute Lung Injury - physiopathology</topic><topic>Adaptor Proteins, Signal Transducing - metabolism</topic><topic>Animal models</topic><topic>Animals</topic><topic>barrier protection</topic><topic>Cell Membrane Permeability - drug effects</topic><topic>Class IIA HDACs inhibition</topic><topic>Contractility</topic><topic>Cytoskeleton</topic><topic>Depletion</topic><topic>Disease Models, Animal</topic><topic>Endothelial cells</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Endotoxins</topic><topic>Heart Rate - drug effects</topic><topic>Histone deacetylase</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Histone Deacetylases - metabolism</topic><topic>Inflammatory diseases</topic><topic>Inhibitors</topic><topic>Lipopolysaccharides</topic><topic>LPS</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Lung - physiopathology</topic><topic>Lungs</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microvasculature</topic><topic>Microvessels - pathology</topic><topic>Models, Biological</topic><topic>Myosin</topic><topic>Oxygen - metabolism</topic><topic>Permeability</topic><topic>Phosphorylation</topic><topic>Pneumonia - complications</topic><topic>Pneumonia - pathology</topic><topic>pulmonary endothelium</topic><topic>Respiratory function</topic><topic>rho GTP-Binding Proteins - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>TMP269</topic><topic>Tubulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovacs‐Kasa, Anita</creatorcontrib><creatorcontrib>Kovacs, Laszlo</creatorcontrib><creatorcontrib>Cherian‐Shaw, Mary</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Meadows, Mary L.</creatorcontrib><creatorcontrib>Fulton, David J.</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovacs‐Kasa, Anita</au><au>Kovacs, Laszlo</au><au>Cherian‐Shaw, Mary</au><au>Patel, Vijay</au><au>Meadows, Mary L.</au><au>Fulton, David J.</au><au>Su, Yunchao</au><au>Verin, Alexander D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>236</volume><issue>4</issue><spage>2893</spage><epage>2905</epage><pages>2893-2905</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization. Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32959895</pmid><doi>10.1002/jcp.30053</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0627-7185</orcidid><orcidid>https://orcid.org/0000-0001-7244-5517</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9541
ispartof Journal of cellular physiology, 2021-04, Vol.236 (4), p.2893-2905
issn 0021-9541
1097-4652
language eng
recordid cdi_crossref_primary_10_1002_jcp_30053
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Acetylation
acute lung injury
Acute Lung Injury - chemically induced
Acute Lung Injury - enzymology
Acute Lung Injury - physiopathology
Adaptor Proteins, Signal Transducing - metabolism
Animal models
Animals
barrier protection
Cell Membrane Permeability - drug effects
Class IIA HDACs inhibition
Contractility
Cytoskeleton
Depletion
Disease Models, Animal
Endothelial cells
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Endotoxins
Heart Rate - drug effects
Histone deacetylase
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - metabolism
Inflammatory diseases
Inhibitors
Lipopolysaccharides
LPS
Lung - drug effects
Lung - pathology
Lung - physiopathology
Lungs
Mice
Mice, Inbred C57BL
Microvasculature
Microvessels - pathology
Models, Biological
Myosin
Oxygen - metabolism
Permeability
Phosphorylation
Pneumonia - complications
Pneumonia - pathology
pulmonary endothelium
Respiratory function
rho GTP-Binding Proteins - metabolism
Signal Transduction - drug effects
TMP269
Tubulin
title Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A28%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20Class%20IIa%20HDACs%20improves%20endothelial%20barrier%20function%20in%20endotoxin%E2%80%90induced%20acute%20lung%20injury&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Kovacs%E2%80%90Kasa,%20Anita&rft.date=2021-04&rft.volume=236&rft.issue=4&rft.spage=2893&rft.epage=2905&rft.pages=2893-2905&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.30053&rft_dat=%3Cproquest_pubme%3E2488831038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2488831038&rft_id=info:pmid/32959895&rfr_iscdi=true